Venus Medtech has agreed a licensing deal with Endoluminal Sciences, an Australian start-up with technology to prevent paravalvular leakage and improve TAVR outcomes.

Venus Medtech, the Chinese transcatheter aortic valve technology specialist, has made its second international acquisition as it pursues its strategy for global expansion in the TAVR market.

Transcatheter Technologies GMBH is preparing to enter the $1.5-1.6 billion Endovascular Aortic Repair market with a product that it says offers advantages over devices that are already available.

Transcatheter Technologies GMBH is preparing to enter the $1.5-1.6 billion Endovascular Aortic Repair market with a product that it says offers advantages over devices that are already available.